Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Camrelizumab + Platinum in HER2+ ESCC
NCT06055153Phase 2Unknown
- Sponsor
- Changhai Hospital
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Changhai Hospital. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06055153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055153.